Navamedic Asa · OSL:NAVA
Navamedic Asa — Q2 2020 Earnings Presentation
20 slides from Navamedic Asa's earnings presentation, 2020
Slide 1: First half and second quarter results 2020
1H/Q2 2020 First half and second quarter results 2020 Navamedic ASA Kathrine Gamborg Andreassen, CEO Lars Hjarrand, CFO
Slide 2: Navamedic – Q2 2020 highlights
Navamedic – Q2 2020 highlights Strengthening our platform for growth • In 1H 2020, revenues grew by 5.5% compared to the same period last year • The portfolio is holding up well although sales was affected by COVID-19 in the quarter REVENUE GROSS MARGIN EBITDA • Completed the acquisition of MA for a
Slide 3: Navamedic at a glance
Navamedic at a glance Nordic pharma company targeting growth in Northern Europe Navamedic - a reliable supplier of high-quality consumer health, medical nutrition, specialty pharma and branded generics products, delivered to hospitals and through pharmacies, meeting the specific medical needs for pa
Slide 4: Our growth strategy continues in 2020
Our growth strategy continues in 2020 Ambition of building a leading Nordic pharma company • Alflorex launched in Denmark (Q1 2020) and will launch in targeting growth in Northern Europe the Netherlands (2H 2020). ThermaCare® launched in July 1 STRENGTHEN THE CORE • Will launch products in at Untapp
Slide 5: Continued growth for key products, although sales was affected by Covid-19
YTD 2020 Continued growth for key products, although sales was affected by Covid-19 in the quarter Medical nutrition Consumer health Branded generics Specialty pharma Medical nutrition Gastro, oral, dermatology, Cardiology, generics Obesity, urology product portfolio pain YTD 2020 YoY revenue growth
Slide 6: Medical nutrition – Continued growth but some volatility due to Covid-19
Strengthen the core Medical nutrition – Continued growth but some volatility due to Covid-19 GROWTH DRIVERS • Upgoing trend for newly YTD 2020 REVENUE launched products 25.2 MNOK • Increased competition from Orphan drugs for PKU (YTD 2019: 23.1 MNOK) • The pandemic had a negative impact on the secon
Slide 7: Consumer Health - launch of new and unique products
Strengthen the core Consumer Health - launch of new and unique products GROWTH DRIVERS • Alflorex® launched in Norway in Q3 2019, Denmark in Q1 YTD 2020 REVENUE 2020 and Iceland in Q2 2020. 12.0 MNOK Launching in the Netherlands in 2H 2020 (YTD 2019: 12.0 MNOK) • Exclusive distribution of ThermaCare
Slide 8: Specialty pharma – awareness and loyalty
Strengthen the core Specialty pharma – awareness and loyalty GROWTH DRIVERS YTD 2020 REVENUE • New reimbursable 24.8 MNOK prescription in Norway • New marketing platform (YTD 2019: 22.9 MNOK) and patient support program 10.9 MNOK in Q2 2020 vs. 11.8 MNOK in Q2 2019 8
Slide 9: Financials @ Navamedic
Financials 9 @ Navamedic
Slide 10: Key consolidated profit and loss figures
Financials • In Q2 2020, revenues came in below the same quarter last year due to negative effect from Key consolidated profit and loss figures the Covid-19 situation, but grew by 5.5% in 1H 2020 compared to last year • Gross Profit % was healthy at 34.8% for the quarter and is above last year YTD •
Slide 11: Financials – Assets
Financials Assets • The increase in goodwill from 31.12.2019 is currency related (in NOK million) 30.06.2020 30.06.2019 31.12.2019 • Investment in associated Intangible assets 8,7 5,6 6,6 company is the equity Goodwill 64,3 58,8 59,5 investment in Observe Medical Investment in associated company 15,
Slide 12: Financials – Equity and liabilities
Financials Equity and liabilities • Equity ratio of 50.6% • Increase in Equity is mainly (in NOK million) 30.06.2020 30.06.2019 31.12.2019 due to cash increase from Equity 131,5 95,4 79,2 the private placement Contingent consideration 0,0 0,0 0,0 Long term part of license liabilities 8,4 10,2 9,6 •
Slide 13: Cash flow Group – total operations
Financials Cash flow Group – total operations • The cash flow from operating activities is (in NOK million) Q2 2020 Q2 2019 YTD 2020 YTD 2019 Year 2019 mostly due to the Net Net cash flow from operating activities -6,3 -2,8 -21,6 6,3 12,7 result and the changes in Net cash flow from investing activi
Slide 14: Summary and outlook
Summary and outlook
Slide 15: Summary and outlook
Navamedic ASA Summary and outlook Building a leading Nordic pharma company targeting growth in Northern Europe In 1H 2020, we have • Strengthened the core by driving growth across the portfolio • Expanded our portfolio through exclusive distribution rights for ThermaCare®, our first product in the i
Slide 16: Q&A @ Navamedic
Q&A 16 @ Navamedic
Slide 17: Thank you for your attention!
Thank you for your attention! Navamedic’s Q3 2020 presentation will be on 6 November, 2020
Slide 18: Appendix
Appendix
Slide 19: Basis for preparation and definitions of Alternative Performance Measures
Appendix Basis for preparation This presentation provides financial highlights for the quarter for Navamedic Group. The financial information is not reported according to the requirements in IAS 34 (Interim Financial Reporting) and the figures are not audited. The same measurement principles as pres
Slide 20: Copyright and disclaimer
Appendix Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Navamedic and third party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be reproduced in any